JESSICA STODIECK: Open Payments
NPI 1073056370 · BURLESON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$518 in 20 payments from 12 companies in 2025. Trend: 2023 $807 · 2024 $362 · 2025 $518
Food & beverage: $419Education: $99
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 2 | $128 |
| Merck Sharp & Dohme LLC | 4 | $86 |
| PFIZER INC. | 2 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| GlaxoSmithKline, LLC. | 2 | $41 |
| Amgen Inc. | 2 | $33 |
| Novartis Pharmaceuticals Corporation | 1 | $30 |
| Boston Scientific Corporation | 1 | $26 |
| AstraZeneca Pharmaceuticals LP | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
Products named: OPSUMIT, VERQUVO, VYNDAQEL, REPATHA, LEQVIO, OPSYNVI, FARAPULSE, ONPATTRO.
Industry payments across TX — which companies pay providers there.
